Skip to content
Home / Media Hub / Resource Library / Tides US 2026 Presentation: PepCellerate™ First-In-Human (FIH) Clinical Trial Supply

Tides US 2026 Presentation: PepCellerate™ First-In-Human (FIH) Clinical Trial Supply

Presentations
Watch this presentation at Tides US 2026 by Tobias Kapp. Learn more about accelerating your peptide therapeutic into Clinical Phase 1 with the integrated CMC development services of PepCellerate™
  • Shortened timelines: ~11 months from sequence to First‑in‑Human clinical trials
  • Parallel peptide API and injectable drug product workflows between teams
  • Proven regulatory track record to support FIH peptide IND/CTA filings
  • Reduced Risk with phase-appropriate GMP infrastructure and fewer handovers

 

Tobias Kapp

Global Head of Peptide Development

Want to find out more?

Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.